Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:54:00.436Z.
Calculation as of: 2026-10-06T19:54:00.436Z.
Quote observation: 2026-10-06T19:50:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 05c00b329f1e3adc6cfa9751fac96b44e9956e0cda8839801cbe896438e656e1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2022-08-08.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.56B
EV/FCF Ratio
N/A
TTM Avg
25.30x
3Y Avg
25.30x
5Y Avg
25.30x
Market Cap
$1.50B
EV/FCF Ratio
101.94x
TTM Avg
58.75x
3Y Avg
43.40x
5Y Avg
42.02x
Market Cap
$1.49B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
EV/FCF Ratio
223.99x
TTM Avg
112.41x
3Y Avg
82.68x
5Y Avg
178.05x
Market Cap
$1.59B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.53B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 6.59x | 8.16x | 9.35x | 8.17x |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.56B | N/A | 25.30x | 25.30x | 25.30x |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 6.00x | 6.42x | 15.96x | 44.16x |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 101.94x | 58.75x | 43.40x | 42.02x |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 223.99x | 112.41x | 82.68x | 178.05x |
| GH Research PLC (GHRS)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | 4.64x | 4.64x | 4.64x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2022-08-08 | 129.15x |
| 2022-08-05 | 126.68x |
| 2022-08-04 | 119.63x |
| 2022-08-03 | 109.33x |
| 2022-08-02 | 106.13x |
| 2022-08-01 | 105.65x |
| 2022-07-29 | 105.59x |
| 2022-07-28 | 110.23x |
| 2022-07-27 | 110.77x |
| 2022-07-26 | 109.39x |
| 2022-07-25 | 110.47x |
| 2022-07-22 | 107.94x |
| 2022-07-21 | 102.52x |
| 2022-07-20 | 98.00x |
| 2022-07-19 | 98.42x |
| 2022-07-18 | 96.25x |
| 2022-07-15 | 97.58x |
| 2022-07-14 | 98.18x |
| 2022-07-13 | 98.42x |
| 2022-07-12 | 97.10x |
| 2022-07-11 | 94.39x |
| 2022-07-08 | 99.93x |
| 2022-07-07 | 101.98x |
| 2022-07-06 | 105.59x |
| 2022-07-05 | 105.59x |
| 2022-07-01 | 97.76x |
| 2022-06-30 | 98.78x |
| 2022-06-29 | 97.82x |
| 2022-06-28 | 94.51x |
| 2022-06-27 | 95.59x |
| 2022-06-24 | 98.12x |
| 2022-06-23 | 97.28x |
| 2022-06-22 | 89.51x |
| 2022-06-21 | 88.12x |
| 2022-06-17 | 84.32x |
| 2022-06-16 | 78.12x |
| 2022-06-15 | 80.65x |
| 2022-06-14 | 77.76x |
| 2022-06-13 | 76.85x |
| 2022-06-10 | 81.49x |
| 2022-06-09 | 86.25x |
| 2022-06-08 | 89.51x |
| 2022-06-07 | 85.05x |
| 2022-06-06 | 79.14x |
| 2022-06-03 | 82.16x |
| 2022-06-02 | 82.88x |
| 2022-06-01 | 82.70x |
| 2022-05-31 | 82.28x |
| 2022-05-27 | 81.19x |
| 2022-05-26 | 74.32x |
| 2022-05-25 | 71.13x |
| 2022-05-24 | 68.24x |
| 2022-05-23 | 70.59x |
| 2022-05-20 | 71.19x |
| 2022-05-19 | 66.13x |
| 2022-05-18 | 65.04x |
| 2022-05-17 | 71.01x |
| 2022-05-16 | 67.33x |
| 2022-05-13 | 67.88x |
| 2022-05-12 | 66.91x |
| 2022-05-11 | 66.01x |
| 2022-05-10 | 74.08x |
| 2022-05-09 | 20.68x |
| 2022-05-06 | 22.45x |
| 2022-05-05 | 23.42x |
| 2022-05-04 | 25.06x |
| 2022-05-03 | 24.61x |
| 2022-05-02 | 24.48x |
| 2022-04-29 | 23.71x |
| 2022-04-28 | 23.99x |
| 2022-04-27 | 22.95x |
| 2022-04-26 | 22.85x |
| 2022-04-25 | 23.66x |
| 2022-04-22 | 23.07x |
| 2022-04-21 | 23.53x |
| 2022-04-20 | 24.44x |
| 2022-04-19 | 24.10x |
| 2022-04-18 | 24.48x |
| 2022-04-14 | 26.21x |
| 2022-04-13 | 26.63x |
| 2022-04-12 | 25.03x |
| 2022-04-11 | 25.43x |
| 2022-04-08 | 25.06x |
| 2022-04-07 | 27.45x |
| 2022-04-06 | 28.08x |
| 2022-04-05 | 28.66x |
| 2022-04-04 | 28.00x |
| 2022-04-01 | 25.26x |
| 2022-03-31 | 24.83x |
| 2022-03-30 | 24.59x |
| 2022-03-29 | 26.41x |
| 2022-03-28 | 24.73x |
| 2022-03-25 | 25.23x |
| 2022-03-24 | 25.61x |
| 2022-03-23 | 25.23x |
| 2022-03-22 | 25.96x |
| 2022-03-21 | 24.04x |
| 2022-03-18 | 23.60x |
| 2022-03-17 | 23.77x |
| 2022-03-16 | 24.26x |
| 2022-03-15 | 22.45x |
| 2022-03-14 | 21.89x |
| 2022-03-11 | 23.86x |
| 2022-03-10 | 25.01x |
| 2022-03-09 | 24.70x |
| 2022-03-08 | 24.13x |
| 2022-03-07 | 23.16x |
| 2022-03-04 | 20.94x |
| 2022-03-03 | 22.47x |
| 2022-03-02 | 22.51x |
